Structure Therapeutics (NASDAQ:GPCR) Stock Rating Upgraded by The Goldman Sachs Group

Structure Therapeutics (NASDAQ:GPCR) was upgraded by investment analysts at The Goldman Sachs Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. Guggenheim raised their price target on shares of Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday. Stifel Nicolaus boosted their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Jefferies Financial Group set a $125.00 target price on shares of Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their price target on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $91.87 on Tuesday. The firm has a market cap of $5.57 billion, a PE ratio of -75.30 and a beta of -2.05. The firm’s 50 day moving average price is $59.82 and its 200 day moving average price is $36.02. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, sell-side analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC raised its holdings in shares of Structure Therapeutics by 6,550.0% in the 2nd quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after buying an additional 6,550 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of Structure Therapeutics by 61.4% during the second quarter. Aberdeen Group plc now owns 401,624 shares of the company’s stock valued at $8,330,000 after acquiring an additional 152,725 shares during the period. Griffin Asset Management Inc. acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $232,000. Allianz Asset Management GmbH bought a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $228,000. Finally, Pacific Heights Asset Management LLC bought a new position in Structure Therapeutics during the 2nd quarter valued at about $9,540,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.